Evogene Ltd Stock price TEL AVIV STOCK EXCHANGE
Equities
IL0011050551
Biotechnology & Medical Research
Sales 2023 | 5.64M 2.08B | Sales 2024 * | 20.3M 7.47B | Capitalization | 37.85M 13.93B |
---|---|---|---|---|---|
Net income 2023 | -23M -8.47B | Net income 2024 * | -20M -7.36B | EV / Sales 2023 | 7.44 x |
Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 1.86 x |
P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 98.27% |
Latest transcript on Evogene Ltd
Managers | Title | Age | Since |
---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-12-31 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 22-03-31 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 04-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 21-11-16 |
Sarit Firon
CHM | Chairman | 58 | 16-08-10 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
1st Jan change | Capi. | |
---|---|---|
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
-8.77% | 11.06B |